Interleukin-2 and interleukin-4 display potent antitumour activity on rat medullary thyroid carcinoma cells

Currently, surgical resection is the only treatment used for human medullary thyroid carcinoma (MTC). However, as metastases are commonly observed, we investigated the potential of adjuvant therapy with interleukin-2 (IL-2) and interleukin-4 (IL-4) in a rat model. The interleukins were delivered by...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 1995-12, Vol.31 (13), p.2379-2384
Main Authors: Cressent, M., Pidoux, E., Cohen, R., Modigliani, E., Roth, C.
Format: Article
Language:English
Subjects:
Animals
Antigens, Neoplasm - analysis
Carcinoma, Medullary - immunology
Carcinoma, Medullary - therapy
Drug Screening Assays, Antitumor
Drug Therapy, Combination
Female
IL-2
IL-4
Interleukin-2 - therapeutic use
Interleukin-4 - therapeutic use
Mice
MTC cells
Rats
Thyroid Neoplasms - immunology
Thyroid Neoplasms - therapy
transduced xenogeneic cells
Transplantation, Heterologous
tumour growth inhibition
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Currently, surgical resection is the only treatment used for human medullary thyroid carcinoma (MTC). However, as metastases are commonly observed, we investigated the potential of adjuvant therapy with interleukin-2 (IL-2) and interleukin-4 (IL-4) in a rat model. The interleukins were delivered by means of xenogeneic tumour cells engineered to secrete IL-2 and IL-4. We found that when a mixture of MTC cells and IL-2 or IL-4 secreting cells were implanted in rats, the growth of the resulting tumours was inhibited as a function of the number of interleukinsecreting cells in the inoculum. Moreover, association of the two interleukins exerted a synergistic antitumour effect. These experimental results, showing thyroid C cell tumour rejection, are of major interest, as they show the potential therapeutic application for these two interleukins, which could be used, in particular, as postsurgical adjuvants.
ISSN:0959-8049
1879-0852
DOI:10.1016/0959-8049(95)00445-9